Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 159 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diffuse Systemic Sclerosis Clear all
Recruiting Phase 2 Interventional

Sildenafil for Early Pulmonary Vascular Disease in Scleroderma

NCT04797286
View directory record Official record
Conditions
Scleroderma, Mildly Elevated Pulmonary Pressures
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
New Orleans, Louisiana • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 9:14 AM EDT
Terminated Not applicable Interventional

Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases

NCT03937856
View directory record Official record
Conditions
Inflammatory Arthritis, Scleroderma, Myositis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Vasculitis
Interventions
Calm- Mindfulness Meditation smartphone application
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 21, 2026, 9:14 AM EDT
Terminated Phase 3 Interventional Results available

GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases

NCT01257802
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Systemic Vasculitis, Isolated Angiitis of Central Nervous System, Lung Disease With Systemic Sclerosis, Lung Disease Interstitial Diffuse
Interventions
depot leuprolide acetate 3.75 mg, Placebo
Drug
Lead sponsor
Joseph Mccune
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 21, 2026, 9:14 AM EDT
Completed No phase listed Observational

The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)

NCT02887495
View directory record Official record
Conditions
Scleroderma
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 100 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 21, 2026, 9:14 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Diffuse Cutaneous Scleroderma (DSSc) SFDI Study

NCT07090226
View directory record Official record
Conditions
Systemic Scleroderma, Diffuse Cutaneous Scleroderma
Interventions
Spatial-frequency domain imaging (SFDI)
Other
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 21, 2026, 9:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Transcutaneous Electroacupuncture for Gastric Complications of Scleroderma

NCT03294616
View directory record Official record
Conditions
Scleroderma, Gastroparesis
Interventions
transcutaneous electroacupuncture
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 21, 2026, 9:14 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 21, 2026, 9:14 AM EDT
Completed Phase 2 Interventional Results available

Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis

NCT02370693
View directory record Official record
Conditions
Lung Diseases, Interstitial, Systemic Sclerosis, Scleroderma
Interventions
Bortezomib, Placebo, Mycophenolate mofetil
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 21, 2026, 9:14 AM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)

NCT04138485
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
IgPro10, Placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 21, 2026, 9:14 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

NCT04440592
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
MT-7117, Placebo
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Glendale, Arizona • Los Angeles, California • Redwood City, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 21, 2026, 9:14 AM EDT
Not yet recruiting Phase 1 Interventional

A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases

NCT07873931
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Lupus Nephritis
Interventions
BMS-986553
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
11
States / cities
Newport Beach, California • Worcester, Massachusetts • Ann Arbor, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 21, 2026, 9:14 AM EDT
Terminated Phase 1 Interventional

A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)

NCT04948554
View directory record Official record
Conditions
Systemic Sclerosis With and Without Interstitial Lung Disease
Interventions
MK-2225, Placebo
Biological
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
11
States / cities
La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 21, 2026, 9:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)

NCT03740724
View directory record Official record
Conditions
Morphea, Scleroderma, Localized, Scleroderma
Interventions
FCX-013, veledimex
Genetic · Drug
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 21, 2026, 9:14 AM EDT
Withdrawn Not applicable Interventional

Functional Luminal Imaging Probe (FLIP) Topography Use in Patients With Scleroderma and Trouble Swallowing

NCT03270722
View directory record Official record
Conditions
Scleroderma, Dysphagia, GERD - Gastro-Esophageal Reflux Disease
Interventions
FLIP topography, Upper Endoscopy
Device · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 21, 2026, 9:14 AM EDT
Completed Phase 1 Interventional

Fresolimumab In Systemic Sclerosis

NCT01284322
View directory record Official record
Conditions
Diffuse Systemic Sclerosis
Interventions
Fresolimumab
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 21, 2026, 9:14 AM EDT
Terminated Phase 2 Interventional Results available

KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis

NCT03919799
View directory record Official record
Conditions
System; Sclerosis, Diffuse Cutaneous Systemic Sclerosis
Interventions
Belumosudil (KD025), Placebo
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years to 100 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 21, 2026, 9:14 AM EDT
Completed No phase listed Observational

Endothelial Function in Patients With Scleroderma or Cirrhosis With and Without Pulmonary Hypertension

NCT01729611
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
17 Years to 90 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 21, 2026, 9:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Scleroderma Registry

NCT00074568
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 21, 2026, 9:14 AM EDT
Recruiting Phase 2 Interventional

EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

NCT07287670
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
MTX-474, Placebo
Biological · Other
Lead sponsor
Mediar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Phoenix, Arizona • La Jolla, California • Loma Linda, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 9:14 AM EDT
Completed Phase 1 Interventional

Mycophenolate Mofetil in Systemic Sclerosis

NCT00433186
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2011 · Synced Oct 21, 2026, 9:14 AM EDT
Completed Not applicable Interventional

Feasibility and Preliminary Effects of the Resilience-based, Energy Management to Enhance Wellbeing in Systemic Sclerosis (RENEW) Intervention

NCT04588714
View directory record Official record
Conditions
Scleroderma
Interventions
Resilience-based, Energy Management to Enhance Wellbeing (RENEW)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 21, 2026, 9:14 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis

NCT04680975
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Belumosudil
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 21, 2026, 9:14 AM EDT
Terminated Phase 3 Interventional

Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis

NCT03398837
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Lenabasum 5 mg, Lenabasum 20 mg, Placebo oral capsule
Drug · Other
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
27
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 21, 2026, 9:14 AM EDT
Withdrawn Phase 2Phase 3 Interventional

CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH

NCT03726398
View directory record Official record
Conditions
Interstitial Lung Disease, Scleroderma, Pulmonary Hypertension
Interventions
Opsumit 10 Mg Tablet
Drug
Lead sponsor
Franz Rischard, DO
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 21, 2026, 9:14 AM EDT